Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

1.4%

8 terminated/withdrawn out of 592 trials

Success Rate

93.4%

+6.9% vs industry average

Late-Stage Pipeline

16%

96 trials in Phase 3/4

Results Transparency

4%

4 of 114 completed trials have results

Key Signals

153 recruiting4 with results

Enrollment Performance

Analytics

N/A
173(45.2%)
Phase 2
70(18.3%)
Phase 4
60(15.7%)
Phase 3
36(9.4%)
Phase 1
25(6.5%)
Early Phase 1
19(5.0%)
383Total
N/A(173)
Phase 2(70)
Phase 4(60)
Phase 3(36)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (592)

Showing 20 of 592 trials
NCT05384444Not ApplicableActive Not Recruiting

Effect of FMD on Colorectal Cancer Patients

Role: collaborator

NCT07620626Recruiting

Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment

Role: collaborator

NCT07639294Completed

The Application of Locoregional Therapy Combined With Systemic Therapy in the Perioperative Period of Huge Hepatocellular Carcinoma: A Retrospective Cohort Study

Role: lead

NCT07637214Completed

A Real-world Study: Analysis of the Efficacy of Antiviral Therapy in CHB Patients Over 30 Years Old, HBV DNA Positive and ALT Normal

Role: lead

NCT07587216Recruiting

Prospective Clinical Database Construction for Liver Cancer Diagnosis and Treatment

Role: lead

NCT07623213Not ApplicableNot Yet Recruiting

AI-Guided Intensified Follow-up After Surgery for Acute Type A Aortic Dissection

Role: collaborator

NCT07444905Active Not Recruiting

Prospective Evaluation of a Locked Risk-Stratified Surveillance Strategy for Extrahepatic Metastasis in Hepatocellular Carcinoma

Role: lead

NCT07350850Phase 2Recruiting

A Multicenter, Prospective Clinical Trial With a Concurrent Control Evaluating Methotrexate Combined With Rituximab,Sintilimab and Pirtobrutinib vs. Investigator-Selected Standard of Care in Treatment-Naive PCNSL

Role: lead

NCT07616271Phase 2Not Yet Recruiting

Study on the Effect of Oral Diammonium Glycyrrhizinate in Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy

Role: lead

NCT07616310Not ApplicableRecruiting

Rectosigmoid Lesion Excision vs. Resection: A Non-Inferiority Randomized Comparison in Advanced Ovarian Cancer

Role: collaborator

NCT07611656Not ApplicableRecruiting

A Multicenter, Prospective, Randomized Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resection on IVF-ET Outcomes in Infertile Patients With Non-recurrent Miscarriage

Role: collaborator

NCT07608224Phase 2Not Yet Recruiting

HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC

Role: collaborator

NCT07606755Phase 4Recruiting

Clinical Efficacy Study of Jinfeng Pill in the Treatment of Perimenopausal Syndrome

Role: lead

NCT07605611Not ApplicableRecruiting

Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resection

Role: lead

NCT06187961Phase 2Active Not Recruiting

HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma

Role: lead

NCT04053205Phase 1Completed

A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Role: collaborator

NCT07159035Not ApplicableActive Not Recruiting

Flexible Ureteroscopy With a Flexible and Navigable Suction Ureteral Access Sheath Versus Mini-Percutaneous Nephrolithotomy for 1-2 cm Lower Pole Kidney Stones

Role: collaborator

NCT07593833Not Yet Recruiting

Prospective Sample Collection Study for a Blood-Based cfDNA Methylation Assay for Ovarian Cancer Detection

Role: lead

NCT05788029Not ApplicableEnrolling By Invitation

Comparing Laparoscopic and Open Pancreaticoduodenectomy for Nonpancreatic Periampullary Adenocarcinomas

Role: lead

NCT07002346Phase 3Recruiting

INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma

Role: lead